论文部分内容阅读
自从1965年以来,美国国立癌症研究所(NCI)一直在开展综合性的药物发展规划,其中包括筛选从天然产物中得到的化合物。规划开展以来,大约已进行了180.000份发酵液对小鼠体内肿瘤活性的筛选,其中8.5%有活性。近几年来,对发酵液进行了体外初筛,初筛有效,才进入体内筛选。而且除链霉菌外还从其他特殊微生物中筛选,因而近年体内活性有了显著的提高。NCI已采用和将采用的体外初筛系统,列于表一。
Since 1965, the National Cancer Institute (NCI) has been conducting a comprehensive drug development program that includes screening of compounds derived from natural products. Approximately 180.000 parts of the fermentation broth has been screened for tumor activity in mice since the program was inaugurated, 8.5% of which is active. In recent years, the fermentation broth in vitro screening, screening effective before entering the body screening. In addition to Streptomyces, it is also screened from other special microorganisms, and in vivo activity has been significantly improved in recent years. The in vitro screening system NCI has adopted and will use is shown in Table 1.